利用血液来源的细胞外基质生物标志物识别中轴型脊柱关节炎患者内型及阿达木单抗治疗应答者
该研究基于三项中轴型脊柱关节炎研究中的14种血液细胞外基质生物标志物进行患者聚类分析,识别出三种内型:高炎症型、低炎症型和高胶原周转型。高炎症型基线ASDAS疾病活动度较高,且第24周阿达木单抗ASDAS临床改善应答比例较高;高胶原周转型第24周BASDAI50应答比例高于低炎症型。这些内型在组织重塑谱上存在差异,未来可能有助于患者分层和治疗定制。
要点
- 基于14种血液细胞外基质生物标志物可识别三种中轴型脊柱关节炎内型:高炎症型、低炎症型和高胶原周转型。
- 高炎症型基线ASDAS疾病活动度高于低炎症型和高胶原周转型,且第24周阿达木单抗ASDAS临床改善应答比例更高。
- 高胶原周转型第24周BASDAI50应答比例高于低炎症型。
核心结论
- 这些内型在组织重塑谱上存在差异,未来可能有助于患者分层和治疗定制。
研究设计与样本
- MASH研究为横断面研究(n=41)。
- ASIM研究为随机、双盲、安慰剂对照试验,阿达木单抗与安慰剂每两周一次治疗6周(n=45)。
- DANISH研究为随机、双盲、安慰剂对照试验,阿达木单抗与安慰剂每两周一次治疗12周(n=49),随后接受主动治疗。
- 检测14种血液细胞外基质生物标志物,经对数转换、均值中心化标准化和标准差缩放后进行主成分分析和K均值聚类以进行患者内型分析。
主要发现
- 识别出两个正交维度:反映炎症和中性粒细胞活性(由C1M和CPa9-HNE驱动)以及胶原周转(由PRO-C2驱动)。
- 识别出三种内型:高炎症内型(内型1)、低炎症内型(内型2)和高胶原周转内型(内型3)。
- 内型1基线ASDAS疾病活动度高于内型2和内型3。
- 内型1第24周基于ASDAS临床改善的阿达木单抗应答患者比例高于内型2和内型3。
- 内型3第24周BASDAI50应答患者比例高于内型2。
关键数值与推荐
- 检测的14种生物标志物包括:胶原形成标志物PRO-C2、PRO-C3、PRO-C6。
- 金属蛋白酶降解胶原标志物C1M、C2M、T2CM、C3M、C4M、C6M、C10C。
- 基质金属蛋白酶降解脯氨酸精氨酸(PROM)、基质金属蛋白酶降解并瓜氨酸化波形蛋白(VICM)。
- 基底膜周转标志物PRO-C4和中性粒细胞活性标志物CPa9-HNE。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the potential of a panel of ECM remodelling markers as endotyping tools for axial spondyloarthritis (axSpA) by separating patients into subtypes and investigate how they differ among each other in disease activity scores and response to treatment with adalimumab. METHODS: In three axSpA studies, a panel of 14 blood-based ECM biomarkers related to formation of collagen (PRO-C2, PRO-C3, PRO-C6), degradation of collagen by metalloproteinases (C1M, C2M, T2CM, C3M, C4M, C6M, C10C), matrix metalloproteinase (MMP)-degraded prolargin (PROM), MMP-degraded and citrullinated vimentin (VICM), basement membrane turnover (PRO-C4) and neutrophil activity (CPa9-HNE) were assessed to enable patient clustering (endotyping). MASH (n=41) was a cross-sectional study, while Adalimumab in Axial Spondyloarthritis study (ASIM,n=45) and Danish Multicenter Study of Adalimumab in Spondyloarthritis (DANISH, n=49) were randomised, double-blind placebo-controlled trials of adalimumab versus placebo every other week for 6 or 12 weeks, respectively, followed by active treatment. Biomarker data were log-transformed, standardised by mean centering and scaled by the SD prior to principal component analysis and K-means clustering. RESULTS: Based on all three studies, we identified two orthogonal dimensions reflecting: (1) inflammation and neutrophil activity (driven by C1M and CPa9-HNE) and (2) collagen turnover (driven by PRO-C2). Three endotypes were identified: high inflammation endotype (Endotype1), low inflammation endotype (Endotype 2) and high collagen turnover endotype (Endotype3). Endotype1 showed higher disease activity (Ankylosing Spondylitis Disease Activity Score (ASDAS)) at baseline compared with Endotype2 and Endotype3 and higher percentage of patients responding to adalimumab based on ASDAS clinical improvement at week 24. Endotype3 showed higher percentage of patients with 50% improvement in Bath Ankylosing Spondylitis Disease Activity Index response at week 24 compared with Endotype2. CONCLUSION: These endotypes differ in their tissue remodelling profile and may in the future have utility for patient stratification and treatment tailoring.
引用
- Port H, Christiansen F, Nielsen SH, et al. Identification of patient endotypes and adalimumab treatment responders in axial spondyloarthritis using blood-derived extracellular matrix biomarkers. RMD Open. 2024. PMID: 38199849. doi:10.1136/rmdopen-2023-003769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。